Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 121 to 130 of 2443 total matches.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
of certain vaccines in adults
residing in the US.1 Routine childhood immunization
has reduced the overall ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Apr 19, 2021 (Issue 1622)
/pseudoephedrine –
Zyrtec-D 12 hour (Johnson & Johnson)
5 mg/120 mg ER tabs OTC 1 tab bid ≥12 yrs: 1 tab bid ...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Dasiglucagon (Zegalogue) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
,
an intranasal powder approved for use in patients
≥4 years old, have been available since 2019.1,2
Injectable ...
The FDA has approved dasiglucagon (Zegalogue –
Zealand) for subcutaneous (SC) treatment of severe
hypoglycemia in patients ≥6 years old with diabetes.
Dasiglucagon is the third glucagon product to be
marketed in the US that does not require reconstitution
before administration; Gvoke, a SC formulation approved for use in patients ≥2 years old, and Baqsimi,
an intranasal powder approved for use in patients
≥4 years old, have been available since 2019.
Injectable glucagon emergency kits (GlucaGen
HypoKit, and generics) have been available for years,
but they require...
Epinastine Ophthalmic Solution (Elestat)
The Medical Letter on Drugs and Therapeutics • Apr 26, 2004 (Issue 1181)
EPINASTINE OPHTHALMIC SOLUTION (ELESTAT)
Epinastine HCl, an H
1
-receptor antagonist and mast ...
Epinastine HCl, an H1-receptor antagonist and mast cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution (Elestat - Allergan/Inspire) for prevention of itching associated with allergic conjunctivitis. The drug is available orally in Europe and Asia.
Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms (online only)
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
symptoms (COWS score
~11-12)
Taper in decrements of 10-20%
every 1-2 days; some patients,
particularly ...
View Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms
Vibegron (Gemtesa) for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
to
be approved in the US; mirabegron (Myrbetriq) was
the first.1
STANDARD TREATMENT — Overactive bladder (OAB ...
The FDA has approved the selective beta-3 adrenergic
agonist vibegron (Gemtesa – Urovant Sciences)
for treatment of overactive bladder in adults with
symptoms of urge urinary incontinence, urgency, and
urinary frequency. It is the second beta-3 agonist to
be approved in the US; mirabegron (Myrbetriq) was
the first.
Oral Fingolimod (Gilenya) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010 (Issue 1353)
to fingolimod phosphate, which interacts with
sphingosine 1-phosphate (S1P) receptors to block lymphocyte ...
The FDA has approved the marketing of fingolimod
(Gilenya – Novartis) to reduce the frequency of clinical
exacerbations and delay the accumulation of physical
disability in patients with relapsing forms of multiple
sclerosis (MS). Fingolimod is the first oral drug
approved for this indication.
Paxlovid for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease ...
On December 22, 2021, the FDA issued an Emergency
Use Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease inhibitor ritonavir (Paxlovid – Pfizer) for
oral treatment of mild to moderate COVID-19 in
outpatients ≥12 years old who weigh at least 40 kg
and are at high risk of progressing to severe disease,
including hospitalization or death. Paxlovid was the
first oral antiviral drug to be authorized in the US for
treatment of COVID-19; Merck's oral antiviral drug
molnupiravir was granted an EUA for treatment of
COVID-19 on...
Fluticasone Furoate (Veramyst) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Nov 05, 2007 (Issue 1273)
for the glucocorticoid receptor is
1.7 times that of fluticasone propionate, and it is a
more potent inhibitor ...
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray (Flonase, and others), which is now available generically.
Bunavail: Another Buprenorphine/Naloxone Formulation for Opioid Dependence
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015 (Issue 1461)
sublingual tablet.1
CLINICAL STUDIES — An unpublished, 12-week, openlabel,
uncontrolled trial conducted ...
The FDA has approved a buccal film formulation of the
partial opioid agonist buprenorphine combined with
the opioid antagonist naloxone (Bunavail – BioDelivery
Sciences) for maintenance treatment of opioid
dependence. Sublingual tablet and film formulations
of the same combination were approved earlier. The
manufacturer of Bunavail claims that the new product
is superior to sublingual formulations because of
the convenience of buccal administration and better
absorption into the blood, permitting use of lower doses.